Mar 13 |
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
|
Feb 9 |
Mineralys: 2nd Half 2024 Hypertension Data Readout
|
Feb 8 |
Mineralys Therapeutics stock jumps on $120M private placement financing
|
Feb 8 |
Mineralys Therapeutics Announces $120 Million Private Placement Financing
|
Jan 29 |
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference
|
Jan 17 |
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know
|
Jan 4 |
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
|
Dec 22 |
Mineralys stock jumps 13% after first patient dosed in hypertension study
|
Dec 21 |
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
|
Nov 27 |
Positive Signs As Multiple Insiders Buy Mineralys Therapeutics Stock
|